Two Novel Mutations Identified in an African-American Child with Chediak-Higashi Syndrome by Morrone, Kerry et al.
Hindawi Publishing Corporation
Case Reports in Medicine
Volume 2010, Article ID 967535, 4 pages
doi:10.1155/2010/967535
Case Report
TwoNovel Mutations Identiﬁedin an African-American Child
withChediak-HigashiSyndrome
Kerry Morrone,1 YanhuaWang,2 MarjanHuizing,3 ElieSutton,1 James G. White,4
William A. Gahl,3 and Karen Moody1
1Children’s Hospital at Monteﬁore, Albert Einstein College of Medicine, Bronx, NY 10467, USA
2Department of Pathology, Monteﬁore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA
3Section on Human Biochemical Genetics, Medical Genetics Branch, National Human Genome Research Institute, NIH,
Bethesda, MD 20814, USA
4Department of Laboratory Medicine, University of Minnesota School of Medicine, Minneapolis, MN 55455, USA
Correspondence should be addressed to Karen Moody, kmoody@monteﬁore.org
Received 30 October 2009; Accepted 4 January 2010
Academic Editor: Franklin O. Smith
Copyright © 2010 Kerry Morrone et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Chediak-Higashi syndrome (CHS) is a rare, autosomal recessive disorder characterized by oculocutaneous albinism,
immunodeﬁciency, coagulopathy and late-onset, progressive neurological dysfunction. It also has an “accelerated phase”
characterized by hemophagocytic lymphohistiocytosis (HLH). The disease is caused by mutations in the CHS1/LYST gene located
on chromosome 1, which aﬀects lysosome morphology and function. We report the case of an African-American child with
CHS in Case. This 16-month old African-American girl presented with fever and lethargy. The proband had pale skin compared
to her parents, with light brown eyes, silvery hair and massive hepatosplenomegaly. Her laboratory evaluation was remarkable
for pancytopenia, high serum ferritin and an elevated LDH. Bone marrow aspirate revealed large inclusions in granulocytes
and erythrophagocytosis consistent with HLH. Genetic evaluation revealed two novel nonsense mutations in the CHS1 gene:
c.3622C > T (p.Q1208X) and c.11002G > T (p.E3668X). Conclusions. Our patient is one of the few cases of CHS reported in the
African American population. We identiﬁed 2 nonsense mutations in the CHS1 gene, the ﬁrst mutation analysis published of an
African-American child with Chediak-Higashi Syndrome. These two mutations predict a severe phenotype and thus identiﬁcation
of these mutations has an important clinical signiﬁcance in CHS.
1.Introduction
Chediak-Higashi Syndrome (CHS) (MIM: 214500) is a
rare autosomal recessive immune disease characterized by
oculocutaneous albinism, a predisposition for infections,
coagulopathies, neurological dysfunction, and large granules
in many cell types [1–3]. CHS is the result of a genetic
defect in the human CHS1/LYST gene (chromosome 1q421-
q42.2), coding for the lysosomal traﬃcking regulator gene
CHS1, resulting in defective formation of secretory vesicles
and lysosomes [3–7]. Patients with CHS contain giant cyto-
plasmic inclusion bodies, large lysosomes, and lysosome-
related organelles such as melanosomes. Patients have an
increased risk of infection due to defects in natural killer
cell activity, T-cell cytotoxicity, chemotaxis, and bactericidal
killing by granulocytes and monocytes. A complication
of CHS is hemophagocytic lymphohistiocytosis (HLH),
which is also known as the “accelerated phase” of the
disorder [5]. This phase is characterized by fever, jaundice,
hepatosplenomegaly, lymphadenopathy, pancytopenia, and
bleeding [8]. Ten to ﬁfteen percent of CHS patients exhibit a
milder clinical phenotype, with fewer or no severe infections
and without an “accelerated phase” of the disease. Though
these patients typically survive to adulthood, they are prone
to developing progressive neurological dysfunction with age
[6, 9].
The exact role of the CHS1 protein is unknown, but has
been better deﬁned through recent studies. CHS1 is thought
toplayaroleinregulatingvesiculartraﬃckingandlysosomal
and lysosome-related organelle size [3, 10, 11]. The milder2 Case Reports in Medicine
Figure 1: Wright stained bone marrow aspirate smear of the
patient with Chediak-Higashi. The arrows in the upper right-
hand side point to histiocytes engulﬁng intact red blood cells.
The arrows in the lower left indicate fragmented red blood cells
(hemophagocytosis).
Figure 2: Peripheral blood smear of our patient with Chediak-
Higashi depicting three polymorphonucelar leucocytes with inclu-
sion bodies. These ﬁndings are typical in Chediak-Higashi syn-
drome.
phenotype of this disease occurs in patients who carry at
least one missense mutation causing a partially functioning
CHD1. Individuals with the more severe CHS phenotype
usuallyhavenullmutantCHS1alleles,predictingtheabsence
of the CHD1 protein. The greater the impairment of the
lysosomal function, the more susceptible an individual is to
infections [3, 5, 6].
The “accelerated phase” is the most life threatening
clinical feature of CHS, due to the high risk of infection
and hemorrhage [5, 8, 12]. Treatments with etoposide and
corticosteroids have resulted in transient remissions, but
relapsesarefrequentandbonemarrowtransplantshavebeen
the only eﬀective cure [8, 12]. The determining factor for
remissionafterbonemarrowtransplantationisdiseasestatus
at transplantation, and transplantation is most successful
when a patient with CHS is not in the “accelerated phase”
[12].
The majority of patients with CHS are generally of
Caucasian or Japanese descent [5]. So far, not more than
5 cases of Chediak-Higashi syndrome in African-American
patients have been described, and to our knowledge, no
mutation analysis in these patients was reported [13–18].
Figure 3: Electron microscopy of a neutrophil granulocyte of our
patient. The arrows show abnormal large cytoplasmic inclusions.
HerewepresentadetailedclinicalpresentationofanAfrican-
American child with CHS, born to nonconsanginous par-
ents. In addition, we describe the CHS1 mutation analysis
identifying two novel nonsense mutations in her CHS1 gene.
2. Case Presentation
Asixteen-month-oldAfrican-Americangirl,presentedtothe
Children’s Hospital at Monteﬁore emergency room with a
history of fever, decreased activity, poor feeding, increased
sleepiness and irritability. She had no nausea, vomiting, diar-
rhea, urinary symptoms, cough or runny nose. The child was
previously healthy, born full term without complications to
a 24-year-old G2P1001 mother. On arrival to the emergency
room she was febrile, tachypneic, tachycardic, and clinically
in respiratory distress.
On examination she was noted to have silvery hair,
blue eyes, and pale skin. Her eyelids were edematous, but
she otherwise had a normal ear, nose, and throat exam.
The heart and lung examination showed sinus tachycardia
and tachypnea, but were otherwise within normal limits.
The patient had a protuberant abdomen with massive
hepatosplenomegaly. She had meningismus, but otherwise
had a grossly normal neurologic exam and normal CSF
studies and culture.
Initial laboratory results revealed pancytopenia, coag-
ulopathy, metabolic acidosis, elevated LDH and normal
uric acid. Our patient received a full sepsis, workup and
was started on broad spectrum antibiotics for febrile neu-
tropenia. The diagnosis of Chediak-Higashi syndrome was
promptly determined after review of the peripheral blood
smear and bone marrow biopsy (Figures 1 and 2). Bone
marrow aspirate revealed large inclusions in myelocytes
and erythrophagocytosis consistent with CHS and HLH.
The bone marrow biopsy was diagnostic with sheets of
histocytes with pale foamy cytoplasm, and pink granules
in neutrophils both consistent with HLH in the accelerated
phase. Electron microscopy revealed large inclusions inCase Reports in Medicine 3
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Figure 4: Hair shaft samples under high powered light microscopy. (a) African-American control hair sample, demonstrating evenly
distributed pigment in the hairshaft. (b) Hair sample of a previously published severely aﬀected Chediak-Higashi syndrome patient [19],
demonstrating an atypical granular distribution of “pigmented clumps” in the hair shaft. (c) Hair sample of our African-American patient
with Chediak-Higashi syndrome, demonstrating a similar atypical granular pigmentation pattern as the CHS patient in (b). All images were
taken at the same settings using a 40X/1.3 oil objective on an Axiovert200M light microscope.
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Figure 5: Two heterozygous nonsense mutations in the CHD1 gene in our patient; p.Q1208X in exon 8 and p.E3668X in exon 50.
the granulocytes diagnostic of CHS (Figure 3). Interestingly
thispatienthadplateletsthatwerehypogranulartoagranular
as seen by electron microscopy, an unusual characteristic
in CHS. Dermatology and genetics specialists assisted in
conﬁrmation of the diagnosis based on their clinical ﬁndings
and the patient’s hair analysis (Figure 4). The patient’s hair
analysis was consistent with other Chediak-Higashi hair
samples [7, 19]. Further questioning of the parents revealed
three maternal uncles had silvery hair, fair skin and frequent
infections as children without any neurologic dysfunction.
The patient received multiple transfusions including
platelets, packed red blood cells, fresh frozen plasma and
cryoprecipitate for her anemia, thrombocytopenia and coag-
ulopathy. Within twenty-four hours of presentation she was
given chemotherapy with etoposide, dexamethasone and
cyclosporine as per protocol [20]. She had an excellent
response after chemotherapy and a repeat bone marrow
showed resolution of the histiocytic inﬁltration. Shortly after
the patient was discharged she had to be readmitted for
hypotensive shock and C diﬃcile colitis. She recovered with
broad spectrum antibiotics with ﬂuid resuscitation and then
wasreferredtoanotherfacility,butunfortunately,thepatient
succumbed to her disease before being able to receive a bone
marrow transplant.
3.MolecularAnalysis
After written consent was obtained, our patient’s blood was
sent for genetic testing to be done at the NIH. Genomic
DNA was investigated for mutations in the CHD1 gene
(GenBank NM 000081). Each of the 53 exons and their sur-
rounding intronic regions were PCR ampliﬁed, sequenced
and analyzed, using standard methods. Two heterozygous
nonsense mutations in CHD1 were identiﬁed (Figure 5).
Exon 5 displayed a c.3622C >Tmutation, resulting in
a change of a glutamine at codon 1208 to a termination
codon (CAG >T A G ; p.Q1208X). And exon 50 contained a
heterozygous c.11002G >Tmutation, resulting in a change
of a glutamic acid at codon 3668 to a termination codon
(GAA >T A A ; p.E3668X). These mutations are predicted to
result in nonsense mediated mRNA decay, and absence of a
translated CHS1 protein.
4. Discussion
Chediak-Higashi syndrome is a rare autosomal recessive
disorder characterized by varying degrees of oculocutaneous
albinism, easy brusability and increased infections [3]. There
is abnormal natural killer cell function with impaired4 Case Reports in Medicine
chemotaxis and bactericidal activity. The underlying defects
involve impaired lysosome-related organelle biogenesis [2, 6,
7, 21, 22].
We describe a case of CHS in the black population.
Her clinical picture, laboratory studies, bone marrow, and
genetic evaluation conﬁrmed CHS. She presented with a
severe phenotype in the accelerated phase of CHS and
had certain unusual phenotypic features such as agranular
platelets. We identiﬁed 2 novel nonsense mutations in the
CHS1 gene (p.Q1208X and p.E3668X), which predict the
absence of a translated CHD1 protein, along with a severe
phenotype as seen in our patient. Hence identiﬁcation of
these mutations has an important clinical signiﬁcance in
predicting the phenotypic severity of patients with CHS.
Furthermore, these mutations are the ﬁrst CHD1 defects
described in the black population, and may serve as a source
for future mutation analysis in this population.
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